GlassScriptPhysician profile
Lambros Stamatakis
NPI 1962641332
$39,315.88
in general payments reported to CMS, 2019-2025
25 companies · $30K in 2025
The $30K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $2,497 · 2021: $860 · 2022: $504 · 2023: $3,770 · 2024: $1,246 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Honoraria: $3,400 · Travel and Lodging: $2,582 · Consulting Fee: $2,300 · Food and Beverage: $2,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,900.00 |
| Honoraria | $3,400.00 |
| Travel and Lodging | $2,582.01 |
| Consulting Fee | $2,300.00 |
| Food and Beverage | $2,110.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $21,004.74 | 2024-2025 | Adstiladrin |
| Immunitybio, INC. | $5,464.62 | 2025 | |
| Urogen Pharma, INC. | $3,762.28 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $2,551.53 | 2020-2025 | Keytruda, Lynparza |
| Janssen Global Services, LLC | $2,332.47 | 2025 | |
| Janssen Scientific Affairs, LLC | $2,043.06 | 2021-2025 | |
| Procept Biorobotics Corporation | $1,015.13 | 2024-2025 | Aquabeam System |
| Axonics, INC. | $315.85 | 2022 | |
| Janssen Biotech, INC. | $215.88 | 2019-2025 | Erleada |
| Photocure INC | $155.37 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $54.22 | 2022-2023 | Pylarify |
| Antares Pharma, INC. | $51.61 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $51.09 | 2024-2025 | |
| Boston Scientific Corporation | $36.69 | 2019-2024 | Ams 700 |
| Intuitive Surgical, INC. | $36.27 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $33.07 | 2023 | Orgovyx |
| Genzyme Corporation | $32.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.08 | 2025 | |
| Coloplast Corp | $23.23 | 2024 | |
| Olympus America INC. | $20.96 | 2023 | Itind System |
| 180 Medical, INC. | $20.88 | 2019 | |
| Teleflex LLC | $19.59 | 2019 | |
| Myovant Sciences INC. | $14.74 | 2022 | |
| Cook Medical LLC | $14.38 | 2024 | Cook |
| Ethicon US, LLC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lambros Stamatakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.